This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Lexatumumab

GlaxoSmithKline plc

Drug Names(s): mAB to TRAIL Receptor 2 -ETR2, HGS-ETR2

Description: HGS-ETR2 is an agonistic human monoclonal antibody that specifically binds to the TRAIL Receptor-2 protein.

Deal Structure: GlaxoSmithKline exercised its option in August 2005 to develop and commercialize HGS-ETR1 jointly with Human Genome Sciences.

As part of its June 1996 agreement with GSK, Human Genome Sciences granted a 50/50 co-development and co-promotion option to GSK for certain Human Genome Sciences human therapeutic products. Under the terms of the agreement, GSK and Human Genome Sciences will share equally development costs and sales and marketing expenses and profits of any product that is commercialized, under a co-development and co-promotion agreement, the remaining terms of which are being negotiated by the parties.

In August 1999, Humane Genome Sciences entered into an antibody license agreement with Cambridge Antibody Technology (CAT) for the development of fully human antibody therapeutics for up to three of Humane Genome Science's target human proteins. Under this 1999 agreement, Humane Genome Sciences has paid CAT $2.3 million for one milestone and fees through the end of...See full deal structure in Biomedtracker

Partners: AstraZeneca PLC


Lexatumumab News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug